Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 4:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Healthy
Interventions: Tolvaptan, Hypertonic saline infusion; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 21 Years to 55 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Interventions: rHSC-DIPGVax, Balstilimab, Zalifrelimab; Biological · Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 12 Months to 18 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Orange, California • Chicago, Illinois • Boston, Massachusetts

Conditions: Adult Solid Tumor
Interventions: SQZ-eAPC-HPV, Pembrolizumab; Biological
Lead sponsor: SQZ Biotechnologies; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 9
States / cities: Scottsdale, Arizona • Duarte, California • Aurora, Colorado + 5 more

Conditions: Solid Tumors, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Colon Cancer, Rectal Cancer, Neoplasms, Endometrial Cancer, Soft Tissue Sarcoma, Triple Negative Breast Cancer, Pancreas Cancer, Pancreatic Cancer
Interventions: LY2880070, Gemcitabine; Drug
Lead sponsor: Esperas Pharma Inc.; Other
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts • Detroit, Michigan

Conditions: Advanced Breast Cancer, Advanced Malignant Solid Tumors, Breast Neoplasms
Interventions: HKI-272, Paclitaxel; Drug
Lead sponsor: Puma Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 8
States / cities: La Jolla, California • San Diego, California • Boston, Massachusetts + 4 more

Conditions: Multiple Sclerosis
Interventions: GLP-1, Ocrelizumab (US); Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Orthopedic Trauma, Sleep Quality
Interventions: Standard Postoperative Care, Zolpidem, Melatonin, Sleep Hygiene Education, Actigraph GT3X-BT Actigraph; Other · Drug · Dietary Supplement + 2 more
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Resectable Esophageal Cancer, GastroEsophageal Cancer
Interventions: Avelumab combined with Chemoradiation, Carboplatin, Paclitaxel, Radiation; Combination Product · Drug · Radiation
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Developmental and Epileptic Encephalopathy 1
Interventions: 1.0mg/kg/day PRAX-562, 1.5mg/kg/day PRAX-562, Placebo; Drug
Lead sponsor: Praxis Precision Medicines; Industry
Eligibility: 2 Years to 65 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: La Jolla, California • Gulf Breeze, Florida • Chevy Chase, Maryland + 3 more

Conditions: Lung Cancer
Interventions: Sputum sample, Pulmonary function tests, Computerized tomography (CT) scan of the chest, Buccal epithelium collection, Nasal brushings, Bronchoscopy, Bronchoalveolar lavage, Blood sample collection, Urine sample, Questionnaire-data collection; Procedure · Radiation · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 55 Years to 80 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: Healthy Subjects
Interventions: Maraviroc (Part 1), Maraviroc (Part 2), Darunavir/cobicistat (Part 2); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: SARS-CoV-2 Infection, COVID-19
Interventions: BNT162b1, BNT162b2, Placebo, BNT162b2SA; Biological · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 12 Years and older
Enrollment: 46,969 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 154
States / cities: Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 106 more

Conditions: Type1diabetes, Insulitis, Pancreas Inflamed
Interventions: Definity Suspension for Injection; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
Interventions: PF-07220060, Letrozole, Fulvestrant, Midazolam, Enzalutamide, Giredestrant, Tamoxifen; Drug · Combination Product · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 14
States / cities: Los Angeles, California • New Haven, Connecticut • Trumbull, Connecticut + 5 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Empowerment and CBT Classes; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 50 Years and older
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Membranous Nephropathy, Nephrotic Syndrome
Interventions: Belimumab, Placebo for Belimumab, Rituximab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 20
States / cities: Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 17 more

Conditions: Mental Health
Interventions: Telephone Reminiscence Program; Behavioral
Lead sponsor: University of Connecticut; Other
Eligibility: 60 Years and older
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Squamous Non-small Cell Lung Cancer
Interventions: Buparlisib, Buparlisib matching placebo, Docetaxel; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 4
States / cities: Fayetteville, Arkansas • Tampa, Florida • Worcester, Massachusetts + 1 more

Conditions: Vomiting, Migraines
Interventions: Not listed
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: Up to 21 Years
Enrollment: 586 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Neoplasms
Interventions: Dostarlimab; Biological
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 729 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 48
States / cities: Birmingham, Alabama • Goodyear, Arizona • Scottsdale, Arizona + 38 more

Conditions: Healthy
Interventions: LY3537982, Itraconazole, Carbamazepine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 2
States / cities: San Antonio, Texas • Salt Lake City, Utah

Conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia
Interventions: Azacitidine, ASTX030 (cedazuridine + azacitidine), Cedazuridine, Venetoclax; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 24
States / cities: Los Angeles, California • Orange, California • New Haven, Connecticut + 18 more

Conditions: Traumatic Brain Injury, Depression
Interventions: In-person Cognitive Behavioral Therapy, Telephone Cognitive Behavioral Therapy; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Quality of Life, Cancer
Interventions: Consultative Specialized Survivorship Clinic (CSSC), Longitudinal Specialized Survivorship Clinic (LSSC), Oncology Embedded Survivorship Clinic (OESC); Other
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Enrollment: 991 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Search by objective public record fields.

Effects of Tolvaptan in Healthy Adults

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer

People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

Sleep Quality and the Efficacy of a Multimodal Sleep Pathway in Hospitalized Orthopedic Trauma Patients

Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer

A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine

Nashville Early Diagnosis Lung Cancer Project

THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

Pancreas Ultrasound Imaging in type1 Diabetes

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

Mood and Diabetes Empowerment & Improvement Training

Belimumab With Rituximab for Primary Membranous Nephropathy

Effect of a Telephone Reminiscence Intervention on Mental Health

Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients

Genetic Analysis of Children With Cyclic Vomiting Syndrome (CVS) and Migraines

Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

A Study of the Effects of Itraconazole or Carbamazepine on LY3537982 in Healthy Participants

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Life Improvement Following Traumatic Brain Injury

Evaluating Cancer Survivorship Care Models